Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Pascale Fouqueray"'
Autor:
Pierre Theurey, Carole Thang, Valdis Pirags, Andrea Mari, Giovanni Pacini, Sébastien Bolze, Sophie Hallakou‐Bozec, Pascale Fouqueray
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 5, Iss 6, Pp n/a-n/a (2022)
Abstract Introduction The aim of the present study was to evaluate the effect of 18‐week monotherapy with imeglimin on glucose tolerance and on insulin secretion/sensitivity in type 2 diabetic (T2D) patients. Methods The study was an 18‐week, dou
Externí odkaz:
https://doaj.org/article/c168b0344ab6477f8ad30762fcf79386
Autor:
Vincent Jacques, Sébastien Bolze, Sophie Hallakou‐Bozec, Anthony W. Czarnik, Ajit S. Divakaruni, Pascale Fouqueray, Anne N. Murphy, Lex H.T. Van der Ploeg, Sheila DeWitt
Publikováno v:
Hepatology Communications, Vol 5, Iss 8, Pp 1412-1425 (2021)
The antidiabetic drug pioglitazone is, to date, the most efficacious oral drug recommended off‐label for the treatment of nondiabetic or diabetic patients with biopsy‐proven nonalcoholic steatohepatitis (NASH). However, weight gain and edema side
Externí odkaz:
https://doaj.org/article/8eba1e4bb6e744a49d5a2d8707b936b2
Autor:
Pierre Theurey, Guillaume Vial, Eric Fontaine, Pierre‐Axel Monternier, Pascale Fouqueray, Sébastien Bolze, David E. Moller, Sophie Hallakou‐Bozec
Publikováno v:
Physiological Reports, Vol 10, Iss 5, Pp n/a-n/a (2022)
Abstract The global prevalence of type 2 diabetes (T2D) is expected to exceed 642 million people by 2040. Metformin is a widely used biguanide T2D therapy, associated with rare but serious events of lactic acidosis, in particular with predisposing co
Externí odkaz:
https://doaj.org/article/3c5c5a0814a54faca6f4b9a67cd60e37
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0241651 (2021)
Pancreatic islet β-cell dysfunction is characterized by defective glucose-stimulated insulin secretion (GSIS) and is a predominant component of the pathophysiology of diabetes. Imeglimin, a novel first-in-class small molecule tetrahydrotriazine drug
Externí odkaz:
https://doaj.org/article/252dbd8ec96f47f7ab59bc8d28490a5c
Autor:
Stephen A. Harrison, Carole Thang, Sébastien Bolze, Sheila Dewitt, Sophie Hallakou-Bozec, Julie Dubourg, Pierre Bedossa, Kenneth Cusi, Vlad Ratziu, Jean-Marie Grouin, David E. Moller, Pascale Fouqueray
Publikováno v:
Journal of Hepatology. 78:914-925
Publikováno v:
Diabetes, Obesity and Metabolism. 24:609-619
To evaluate the safety and efficacy of imeglimin for 52 weeks as monotherapy or combination therapy with existing antidiabetic agents in Japanese patients with type 2 diabetes.TIMES 2 was a phase 3, pivotal, open-label trial including patients with t
Autor:
Julie Dubourg, David E. Moller, Sébastien Bolze, Jean-Marie Grouin, Naim Alkhouri, Sophie Hallakou-Bozec, Pascale Fouqueray, Stephen A. Harrison, Vlad Ratziu, Kenneth Cusi, S. Megnien
Publikováno v:
The Lancet Gastroenterology & Hepatology. 6:889-902
Summary Background AMP kinase (AMPK) is an energy sensor implicated in regulation of lipid metabolism, inflammation, and insulin sensitivity. We aimed to assess efficacy and safety of PXL770, a novel direct AMPK activator, in patients with non-alcoho
Autor:
Sophie Hallakou-Bozec, Anne N. Murphy, Lex H.T. Van der Ploeg, Pascale Fouqueray, Vincent Jacques, Sheila Dewitt, Sébastien Bolze, Ajit S. Divakaruni, Anthony W. Czarnik
Publikováno v:
Hepatology Communications, Vol 5, Iss 8, Pp 1412-1425 (2021)
The antidiabetic drug pioglitazone is, to date, the most efficacious oral drug recommended off-label for the treatment of nondiabetic or diabetic patients with biopsy-proven nonalcoholic steatohepatitis (NASH). However, weight gain and edema side eff
Publikováno v:
Clinical drug investigation. 42(9)
Imeglimin is a first-in-class novel oral antidiabetic marketed in Japan as TWYMEEGTo assess the pharmacokinetic and safety profile of imeglimin in Caucasian and Japanese healthy individuals.Two randomized placebo-controlled phase 1 clinical studies w
Publikováno v:
Diabetes, Obesity & Metabolism
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2021, 23 (3), pp.800-810. ⟨10.1111/dom.14285⟩
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2021, 23 (3), pp.800-810. ⟨10.1111/dom.14285⟩
International audience; AIMS: The aim of this study was to assess the efficacy and safety of imeglimin monotherapy compared to placebo for 24 weeks in Japanese patients with type 2 diabetes mellitus (T2DM).MATERIAL AND METHODS: In this 24-week, rando